Review Article
Split Viewer
Blood Res 2023; 58(S1):
Published online April 30, 2023
https://doi.org/10.5045/br.2023.2023004
© The Korean Society of Hematology
Transfusion support in hematopoietic stem cell transplantation
Correspondence to : Yonggoo Kim, M.D., Ph.D.
Departments of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Banpo-dong, Seocho-gu, Seoul 06591, Korea
E-mail: yonggoo@catholic.ac.kr
*This study was supported by a grant from National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2021R1F1A1046464).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.
Keywords Transfusion, Hematopoietic stem cell transplantation, ABO blood group, RhD blood group
PDF
Standard view
Export citation
Share Article
Review Article
Blood Res 2023; 58(S1): S1-S7
Published online April 30, 2023 https://doi.org/10.5045/br.2023.2023004
Copyright © The Korean Society of Hematology.
Transfusion support in hematopoietic stem cell transplantation
Dong Wook Jekarl1, Jae Kwon Kim1, Jay Ho Han1, Howon Lee1, Jaeeun Yoo2, Jihyang Lim3, Yonggoo Kim1
Departments of Laboratory Medicine, 1Seoul St. Mary’s Hospital, College of Medicine, Seoul, 2Incheon St. Mary’s Hospital, College of Medicine, Incheon, 3Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Correspondence to:Yonggoo Kim, M.D., Ph.D.
Departments of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Banpo-dong, Seocho-gu, Seoul 06591, Korea
E-mail: yonggoo@catholic.ac.kr
*This study was supported by a grant from National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2021R1F1A1046464).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.
Keywords: Transfusion, Hematopoietic stem cell transplantation, ABO blood group, RhD blood group
Fig 1.
Download
-
Table 1 . Donor and recipient relationship associated with RhD..
Donor antigen Recipient antigen D negative with anti-D D negative without anti-D D positive D negative with anti-D Identical Identical Minor incompatibility D negative without anti-D Identical Identical Minor mismatch D positive Major incompatibility Major mismatch Identical
-
Table 2 . Transfusion strategy for peritransplantion..
ABO incompatibility Recipient Donor Phase I Phase II Phase III All product RBC PLT 1st PLT 2nd Plasma All product Major O A Recipient O A AB, B, O A Donor O B Recipient O B AB, A, O B Donor O AB Recipient O AB A, B, O AB Donor A AB Recipient A AB A, B, O AB Donor B AB Recipient B AB B, A, O AB Donor Minor A O Recipient O A AB, B, O A Donor B O Recipient O B AB, A, O B Donor AB O Recipient O AB A, B, O AB Donor AB A Recipient A AB A, B, O AB Donor AB B Recipient B AB B, A, O AB Donor Bidirectional A B Recipient O AB B, A, O AB Donor B A Recipient O AB A, B, O AB Donor
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Prognostic impact of total body irradiation dose in pediatric acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation in second complete remission
Wonjin Jang, Suejung Jo, Jae Won Yoo, Seongkoo Kim, Jae Wook Lee, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho
Blood Res 2022; 57(4): 256-263 -
Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
Dong Hyun Kim, Jeongmin Seo, Dong-Yeop Shin, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Ja Min Byun
Blood Res 2022; 57(4): 264-271 -
Favorable outcomes with durable chimerism after hematopoietic cell transplantation using busulfan and fludarabine-based reduced-intensity conditioning for pediatric patients with hemophagocytic lymphohistiocytosis
Jin Kyung Suh, Young Kwon Koh, Sung Han Kang, Hyery Kim, Eun Seok Choi, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(2): 152-157
